SGRY Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Proposed Sale of Surgery Partners to HealthSpan Partners
Globe Newswire•04/11/2026•09:45 ET
0
Key Highlights
- ➤Surgery Partners sale proposed at $23.50 per share in cash
- ➤Bain will roll over all SGRY shares for equity in the surviving entity
- ➤Wohl & Fruchter is investigating Special Committee independence and sale fairness
Expert Statements
Joshua Fruchter, Founding partner of Wohl & Fruchter
“We are investigating whether the SGRY Board acted in the best interests of SGRY stockholders in approving the sale. This includes whether the members of the Special Committee that recommended the sale were independent and disinterested, whether the price is fair to SGRY stockholders and whether all material information regarding the transaction has been fully disclosed. We encourage SGRY stockholders to contact us if they have any concerns.”
MONSEY, N.Y., Nov. 04, 2026 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of Surgery Partners, Inc. (NASDAQ: SGRY) (“SGRY”) to HealthSpan Partners for $23.50 per share in cash.
The sale was approved upon the recommendation of a Special Committee of SGRY’s Board of Directors, which merits investigation into whether the members of the Special Committee were truly independent and disinterested.
Get started
Create a free account to read the full story.